• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Biocon Limited - Product Pipeline Review - Q4 2010 - Product Image

Biocon Limited - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • 71 pages
  • Global Markets Direct

Biocon Limited – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Biocon Limited - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Biocon Limited - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Biocon Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the READ MORE >



List of Tables
List of Figures
Biocon Limited Snapshot
Biocon Limited Overview
Key Information
Key Facts
Biocon Limited – Research and Development Overview
Key Therapeutic Areas
Biocon Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Biocon Limited – Pipeline Products Glance
Biocon Limited – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Biocon Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Biocon Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Biocon Limited – Drug Profiles
IN-105
Product Description
Mechanism of Action
R&D Progress
T1h
Product Description
Mechanism of Action
R&D Progress
Bmab 100
Product Description
Mechanism of Action
R&D Progress
Bmab 200
Product Description
Mechanism of Action
R&D Progress
BVX-10
Product Description
Mechanism of Action
R&D Progress
BVX-20
Product Description
Mechanism of Action
R&D Progress
IN-105
Product Description
Mechanism of Action
R&D Progress
PEG-GCSF
Product Description
Mechanism of Action
R&D Progress
Cancer Vaccine
Product Description
Mechanism of Action
R&D Progress
Biocon Limited – Pipeline Analysis
Biocon Limited – Pipeline Products by Therapeutic Class
Biocon Limited Pipeline Products By Target
Biocon Limited – Pipeline Products by Route of Administration
Biocon Limited – Pipeline Products by Molecule Type
Biocon Limited - Dormant Projects
Biocon Limited – Company Statement
Biocon Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 29, 2009: Biocon Plans Oral Insulin (IN-105) To Launch In 18 Months
Sep 11, 2009: Biocon Limited And Amylin Pharmaceuticals Enter A Global Development And Commercialization Agreement For A Novel Peptide Hybrid
Sep 08, 2008: Biocon Limited Presents Human Clinical Data On IN-105 (Oral Insulin) At The EASD Meeting In Rome
Sep 21, 2007: Biocon Limited Presents Human Clinical Data On IN-105 (Oral Insulin) At The EASD Meeting In Amsterdam
Mar 28, 2006: Biocon Wins Bid For Acquiring Nobex's Oral BNP
Oct 01, 2005: Nobex And Biocon Collaborate To Develop Oral BNP Product
Financial Deals Landscape
Biocon Limited, Deals Volume Summary, 2004 to YTD 2010
Biocon Limited, Deals Summary By Region, 2004 to YTD 2010
Biocon Limited, Deals Summary, 2004 to YTD 2010
Biocon Limited Detailed Deal Summary
Asset Purchase
Biocon Sells Its Enzymes Business To Novozymes
Acquisition
Biocon Acquires IDL Specialty Chemicals From Gulf Oil Corporation
Biocon Acquires 70% Stake In AxiCorp
Biocon Acquires Minority Stakes In IATRICa
Equity Offering
Vaccinex Completes Private Placement Of $1 Million
Nobex Completes Private Placement Of $1 Million
Biocon Completes Initial Public Offering Of $70 Million
Amylin Enters Into Co-Development Agreement With Biocon
Mylan Enters Into Agreement With Biocon
Biocon Enters Into A Strategic Partnership With IATRICa
Biocon Forms Joint Venture With Neopharma
Biocon Signs A Licensing Agreement With Bentley Pharmaceuticals
Clinigene And SCIREX Collaborate On Global Clinical Trials
Biocon Enters Into A Global Research Collaboration Agreement With Nobex
Biocon Enters Into A Strategic Partnership With Vaccinex
Biocon Enters Into A Research Collaboration Agreement With Nobex
Licensing Agreements
Abraxis BioScience Enters Into Licensing Agreement With Biocon
Abraxis BioScience Enters Into Licensing Agreement With Biocon
Biocon Enters Into An Exclusive Licensing Agreement With Ferozsons Laboratories
Biocon Enters Into Licensing Agreement With Bayer HealthCare For INSUGEN
Biocon Announces Licensing Agreement For Oral Insulin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS